Original cells | Stress | Biological function | Refs. |
---|---|---|---|
Ordinary tumor cells | UV | Mediating M2 polarization of TAMs and promoting tumor growth and metastasis | [163] |
Loading PD-L1 and inhibiting activation of CD8+ T cells | [68] | ||
Facilitating the generation of type I IFN in DCs and promoting their activation through cGAS/STING signaling | [71] | ||
Up-regulating expression of CCL2 in IECs to attract and activate DCs for tumor inhibition | [59] | ||
Augmenting biogenesis and centripetal movement of lysosomes in tumor cells | [77] | ||
X ray | Causing ferroptosis in tumor cells and mediating M1 polarization of TAMs | [58] | |
Activating stromal cells to secrete pro-angiopoietic factors | [66] | ||
Inhibiting antitumor immunity with the carried PD-L1 | |||
Hypoxia | Mediating M2 polarization of TAMs | [163] | |
Up-regulating expression of CCL2 in lung macrophages and promoting lung metastasis | [164] | ||
Activating fibroblasts and endothelial cells to express pro-angiopoietic factors | [66] | ||
Inhibiting the functions of NK cells by transferring miR-23a | [165] | ||
Promoting focal adhesion formation, tumor invasion and metastasis | [35] | ||
No treatment | Inhibiting the activation of B cells and promoting the release of anti-inflammatory cytokines from monocytes | [166] | |
Promoting antiapoptotic effect on monocytes by transferring CCR6 and CD44v7/8 | [167] | ||
Promoting the differentiation of myeloid cells and enhancing their function on inhibiting T cells activation | [168] | ||
Inducing lymphocyte apoptosis by the carried FasL | [169] | ||
Promoting Treg differentiation and enhancing their negative regulation of immunity | [170] | ||
Promoting differentiation of monocytes to macrophages | [171] | ||
Up-regulating VEGF expression in endothelial cells by the carried epidermal growth factor receptor | [172] | ||
Inducing IL-10 production in monocytes by the carried hyaluronan | [173] | ||
Modulating antigen cross-processing in DCs through the packaged ROS | [174] | ||
Inducing premetastatic cell clusters and promoting liver metastasis by the carried CD36 | [175] | ||
Converting normal fibroblasts into carcinoma-associated fibroblasts (CAFs) by the carried miR-155 | [176] | ||
Up-regulating expression of transforming growth factor β in macrophages by the carried phosphatidylserine | [177] | ||
Starvation | Converting normal fibroblasts into CAFs by phosphorylating ERK1/2 and down-regulating caveolin1 | [178] | |
Up-regulating activity of focal adhesion kinase in epithelial cells and then reorganizing extracellular matrix | [179] | ||
Apoptogenic reagents | Activating fibroblasts through phosphorylating ERK1/2 and up-regulating MMP9 | [180] | |
Chemo-resistant tumor cells | No treatment | Transferring resistance proteins to drug-sensitive tumor cells | |
Down-regulating miR-503 and up-regulating proline-rich tyrosine kinase 2 of tumor cells to promote tumor migration and invasion | [184] | ||
Increasing the release of IL-6, TNF-α and INF-γ in macrophages | [185] | ||
Stem-cell-like cancer cells | No treatment | Converting normal endothelial cells into an activated angiogenic phenotype and promoting the formation lung premetastatic niche | [186] |
Transferring tissue factor and accelerating plasma coagulation | [187] | ||
Endothelial cells | Starvation | Activating angiogenesis in recipient cells by transferring mRNA | [188] |
Promoting anti-inflammatory effects by transferring miR-222 and reducing ICAM-1 expression in endothelial cells | [189] | ||
TNF-α | Up-regulating the expression of ICAM-1 in endothelial cells | [190] | |
Converting endothelial cells into an anti-atherogenic phenotype by transferring miR-126, miR-21 and miR-155 | [191] | ||
Inducing plasmacytoid DCs maturation and production of inflammatory cytokines Promoting proliferation and production of IFN-γ and TNF-α in CD4+ T cells | [192] | ||
Increasing monocyte adhesion by up-regulating the expression of ICAM-1 in endothelial cells Mediating apoptosis and inflammation of endothelial cells | [36] | ||
CAFs | No treatment | Promoting generation of stem-cell-like cancer cells and resistance to hormonal therapy by transferring miR-221 | [193] |
Platelets | No treatment | Inducing angiogenesis through VEGF, heparanase, and platelet derived growth factor | [194] |
Stimulating proliferation and invasion of tumor cells by transferring integrin CD41 | [195] | ||
Inducing epithelial to mesenchymal transition in tumor cells by transferring miR-939 | [60] | ||
Mediating mitochondrial dysfunction and growth inhibition in tumor cells by transferring miR-24 | [196] | ||
Promoting angiogenesis, tissue regeneration and cancer metastasis | [61] | ||
ADP | Increasing the production of lipoxin A4 in mast cells by transferring ipoxygenase 12 | [197] | |
High-shear | Increasing the expression of IL-8, IL-1β and TNF-α in macrophages Up-regulating the production of IL-8, IL-1β and IL-6 in endothelial cells | [198] | |
TNF-α | Incapable of inducing plasmacytoid DCs maturation | [192] | |
Erythrocytes | Hypotonic solutions | Falsely “mark” nucleated cells as apoptotic by transferring phosphatidylserine | [42] |
Monocytes | LPS | P-selectin glycoprotein ligand-1 on the MPs interacted with P-selectin on the platelets and activated platelets to initiate coagulation | [199] |
Promoting pro-inflammatory and procoagulant properties of endothelial cells by transferring transcripts of pro-inflammatory cytokines such as TNF-α, IL-6 and IL-8 | [200] | ||
No treatment | Promoting angiogenesis by transferring miR-150 to endothelial cells | [201] | |
Macrophages | LPS | Inducing expression of ICAM-1 and release of keratinocyte-derived cytokine by transferring TNF-α | [202] |
Lm infection | Transferring antigens of Listeria monocytogenes (Lm) to DCs for antigen presentation | [203] | |
T lymphocytes | Inducers of apoptosis | Inducing apoptosis and stimulating release of MPs in macrophages | [204] |
Starvation | Converting fibroblasts into osteoclasts by up-regulating IL-15, MMP9 and receptor activator of NF-κB ligand in odontogenic keratocysts | [205] | |
TNF-α | Incapable of inducing plasmacytoid DCs maturation | [192] | |
UV | Incapable of mediating M2 polarization of TAMs | [163] | |
No treatment | Inhibiting growth and migration of retinal endothelial cells in vitro, and decreasing VEGF-induced retinal vascular leakage in vivo | [206] | |
Splenic cells | PMA | Increasing tumor metastasis by transferring integrin α(M)β2 | [207] |
Yeast cells | NaOH and heat | Activating DCs through Dectin-1/Syk pathway and TLR2/MyD88 pathway | [78] |